Philip Chen

3 weeks ago | journals.sagepub.com | Philip Chen |Ashley Sorensen

Get full access to this articleView all access and purchase options for this article. ReferencesAndersen David J., Ditonto Tessa. 2020. “The Importance of Candidate Sex and Partisan Preference over Time: A Multiday Study of Voter Decision Making.” The Journal of Politics 82 (4): 1337–53. Atkeson Lonna Rae. 2003. “Not All Cues Are Created Equal: The Conditional Impact of Female Candidates on Political Engagement.” The Journal of Politics 65 (4): 1040–61. Atkeson Lonna Rae, Carrillo Nancy. 2007.

Aug 11, 2024 | linkedin.com | Philip Chen

ai world. tv Sydney Armani Sydney Armani Chairman & CEO | AI Fintech World Ventures | Artificial intelligence | Blockchain | AI Media | Published Aug 12, 2024 By Philip Chen on August 12, 2024,  As someone who browses the web daily, I find myself increasingly concerned about how my personal information is used, especially with the lurking threats of the dark web.

Jun 11, 2024 | journals.sagepub.com | Philip Chen |Amanda Savage

Get full access to this articleView all access and purchase options for this article. ReferencesAlexander Michelle. The New Jim Crow: Mass Incarceration in the Age of Colorblindness. New York, NY: The New Press, 2012. Andersen David J., Ditonto Tessa. 2020. “The Importance of Candidate Sex and Partisan Preference over Time: A Multiday Study of Voter Decision Making.” The Journal of Politics 82 (4): 1337–1353. Arnesen Sveinung, Duell Dominik, Johannesson Mikael Poul. 2019.

Apr 8, 2024 | jdsupra.com | Philip Chen |Andria Rae Crisler |Casey Kraning Ph.D

In this review, we discuss the most important recent developments in the biosimilars space, including new biosimilar approvals and launches, litigation under the Biologics Price Competition and Innovation Act (BPCIA), post-grant disputes on biologic drug patents before the United States Patent and Trademark Office (USPTO), and proposed legislation and regulatory activities relating to biosimilars.

Apr 5, 2024 | fr.com | Andria Rae Crisler |Casey Kraning |Philip Chen |Madelyn McCormick

In this review, we discuss the most important recent developments in the biosimilars space, including new biosimilar approvals and launches, litigation under the Biologics Price Competition and Innovation Act (BPCIA), post-grant disputes on biologic drug patents before the United States Patent and Trademark Office (USPTO), and proposed legislation and regulatory activities relating to biosimilars.